Torrent Pharmaceuticals Sustainability Profile
Torrent Pharmaceuticals Limited, commonly known as Torrent Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Ahmedabad, India. Founded in 1959, the company has established a strong presence in various operational regions, including North America, Europe, and emerging markets across Asia and Africa. Specialising in the development, manufacturing, and marketing of a diverse range of generic and branded pharmaceuticals, Torrent Pharma focuses on therapeutic areas such as cardiovascular, central nervous system, and anti-infectives. The company is recognised for its commitment to quality and innovation, which has led to significant milestones, including a robust portfolio of over 200 products. With a strong market position, Torrent Pharmaceuticals has garnered accolades for its research and development capabilities, making it a trusted name in the industry. Its dedication to improving patient outcomes through affordable healthcare solutions sets it apart in a competitive landscape.
DitchCarbon Score
How does Torrent Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Torrent Pharmaceuticals's score of 29 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Torrent Pharmaceuticals's reported carbon emissions
In 2025, Torrent Pharmaceuticals reported significant carbon emissions, with Scope 1 emissions totalling approximately 8,937,000 kg CO2e and Scope 2 emissions at about 78,592,000 kg CO2e. Additionally, their Scope 3 emissions reached approximately 154,837,270 kg CO2e, which includes substantial contributions from purchased goods and services (about 67,010,170 kg CO2e) and business travel (approximately 23,182,710 kg CO2e). The company has disclosed emissions data for both Scope 1 and Scope 2, but there is no specific reduction target or climate pledge noted in their current commitments. The emissions data is cascaded from Torrent Pharmaceuticals Limited, indicating a corporate family relationship. In previous years, emissions have shown variability, with 2024 reporting Scope 1 emissions of about 15,294,000 kg CO2e and Scope 2 emissions of approximately 76,268,000 kg CO2e. In 2023, the figures were 25,063,000 kg CO2e for Scope 1 and 97,111,000 kg CO2e for Scope 2. Overall, while Torrent Pharmaceuticals has made strides in emissions reporting, the absence of specific reduction targets highlights an area for potential improvement in their climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 28,072,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 96,026,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Torrent Pharmaceuticals's Industry?
How Carbon Intensive is Torrent Pharmaceuticals's Location?
Torrent Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Torrent Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
